Healthcare resource utilisation and costs in patients with treated obstructive sleep apnea
Journal of Sleep Research · 2024
DOI: 10.1111/jsr.14099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Sleep Research, 2024. Verfasst von Kimberly L Sterling und 7 weiteren Autor:innen. Beteiligte Einrichtung: ResMed Science Center, San Diego, California, USA. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Continuous Positive Airway Pressure, Health Care Costs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, ResMed.
Abstract (Originalsprache)
Obstructive sleep apnea (OSA) is a highly prevalent yet underdiagnosed disease that creates a large economic burden on the United States healthcare system. In this retrospective study, we tested the hypothesis that adherence to positive airway pressure (PAP) therapy, the ‘gold standard’ treatment for OSA, is associated with reduced healthcare resource utilisation and costs. We linked de‐identified payer‐sourced medical claims and objective PAP usage data for patients newly diagnosed with OSA. Inverse probability of treatment weighting was used to create balanced groups of patients who were either adherent, intermediately adherent, or non‐adherent to PAP therapy. From a sample of 179,542 patients (average age 52.5 years, 61% male), 37% were adherent, 40% intermediate, and 23% non‐adherent. During the first year, PAP adherence was significantly associated with fewer emergency room visits (mean [SD] adherent: 0.39 [1.20] versus intermediate: 0.47 [1.30], p < 0.001; versus non‐adherent: 0.54 [1.44], p < 0.001), all‐cause hospitalisations (mean [SD] adherent: 0.09 [0.43] versus intermediate: 0.12 [0.51], p < 0.001; versus non‐adherent: 0.13 [0.55], p < 0.001), and lower total costs (mean [SD] adherent $5874 [8045] versus intermediate $6523 [9759], p < 0.001; versus non‐adherent $6355 [10,517], p < 0.001). Results were similar in the second year of PAP use. These results provide additional evidence from a large, diverse sample to support the diagnosis and treatment of OSA and encourage long‐term adherence to PAP therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ResMed Science Center, San Diego, California, USA.
- Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Institute National de la Sante et de la Recherche Medicale (INSERM) U 1300, HP2 Laboratory (Hypoxia: Pathophysiology), Grenoble Alpes University, Grenoble, France.
- ResMed Science Center, Halifax, Nova Scotia, Canada.
- University of California San Diego, La Jolla, California, USA.
ORCID-Profile: Kimberly L Sterling, Naomi Alpert, Peter A Cistulli, Jean-Louis Pépin, Suyog More, Kate V Cole, Atul Malhotra
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- ResMed
Zitieren
APA
Sterling, K. L., Alpert, N., Cistulli, P. A., Pépin, J. L., More, S., Cole, K. V., Malhotra, A., & medXcloud group (2024). Healthcare resource utilisation and costs in patients with treated obstructive sleep apnea. Journal of Sleep Research. https://doi.org/10.1111/jsr.14099
Vancouver
Sterling KL, Alpert N, Cistulli PA, Pépin JL, More S, Cole KV, et al. Healthcare resource utilisation and costs in patients with treated obstructive sleep apnea. Journal of Sleep Research. 2024. doi:10.1111/jsr.14099
BibTeX
@article{Sterling2024,
author = {Sterling, Kimberly L and Alpert, Naomi and Cistulli, Peter A and Pépin, Jean-Louis and More, Suyog and Cole, Kate V and Malhotra, Atul and medXcloud group, medXcloud group},
title = {Healthcare resource utilisation and costs in patients with treated obstructive sleep apnea},
journal = {Journal of Sleep Research},
year = {2024},
doi = {10.1111/jsr.14099}
}
EUVIMED